$PYXS News

Pyxis Oncology Q1 EPS $(0.37), Inline

Wedbush Initiates Coverage On Pyxis Oncology with Outperform Rating, Announces Price Target of $6

Pyxis Oncology To Reveal New Preclinical Data Demonstrating Synergistic Anti-Tumor Activity In A HNSCC Model With maMICVO In Combination With Anti-PD-1 at AACR 2026

HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

Pyxis Oncology Q4 EPS $(0.29) Beats $(0.33) Estimate, Sales $11.038M

Pyxis Oncology Appoints Thomas Civik As Interim CEO, Effective Immediately; Lara Sullivan Steps Down As President, CEO And Chief Medical Officer

Pyxis Oncology Appoints Thomas Civik As Interim CEO, Effective Immediately; Lara Sullivan Steps Down As President, CEO And Chief Medical Officer

3 Promising Penny Stocks With Market Caps Up To $300M

RBC Capital Maintains Outperform on Pyxis Oncology, Lowers Price Target to $5

Analysts Sound Alarm On Pyxis Oncology's Tiny Trial

HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $7

Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript

12 Health Care Stocks Moving In Thursday's Intraday Session

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma - Slideshow

Dow Surges 400 Points; Accenture Earnings Top Views

Pyxis Oncology shares are trading lower. The company announced preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin.

Pyxis Oncology Shares Early Phase 1 Data For MICVO Showing Meaningful Clinical Activity In Recurrent Or Metastatic Head And Neck Cancer

Pyxis Oncology Files For Mixed Shelf Of Up To $350M And Also Files For $150M Stock Sale Agreement With Leerink Partners

Stephens & Co. Maintains Overweight on Pyxis Oncology, Raises Price Target to $8